Literature DB >> 17437612

Plasma lipid peroxidation and progression of disability in multiple sclerosis.

M Koch1, J Mostert, A V Arutjunyan, M Stepanov, A Teelken, D Heersema, J De Keyser.   

Abstract

Oxidative stress has been implicated in the pathophysiology of multiple sclerosis (MS), but its relation to disease progression is uncertain. To evaluate the relationship of plasma lipid peroxidation with progression of disability in MS, we measured blood plasma fluorescent lipid peroxidation products (PFLPP) levels in 23 patients with RRMS with a benign course, 32 with secondary progressive MS, 24 with primary progressive MS and 30 healthy controls. None of the patients had a relapse within the previous 3 months. Progression of disability was evaluated during a follow-up period of 5 years by the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSSS). We found plasma PFLPP levels elevated in patients with MS compared with controls (P < 0.0001), but there was no difference between patients with a benign and progressive disease course. There was no correlation between PFLPP levels and worsening of disability on the EDSS and speed of progression on the MSSS. Our data suggest that there is no relation between the degree of oxidative stress in plasma and progression of disability in MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437612     DOI: 10.1111/j.1468-1331.2007.01739.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  20 in total

1.  Relationship between thiol-disulphide homeostasis and visual evoked potentials in patients with multiple sclerosis.

Authors:  Gönül Vural; Şadiye Gümüşyayla; Orhan Deniz; Salim Neşelioğlu; Özcan Erel
Journal:  Neurol Sci       Date:  2018-12-01       Impact factor: 3.307

2.  Cerebrospinal fluid and plasma oxidative stress biomarkers in different clinical phenotypes of neuroinflammatory acute attacks. Conceptual accession: from fundamental to clinic.

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Slobodan Vojinovic; Dragan Stojanov; Svetlana Stojanovic; Gordana Kocic; Dejan Savic; Tatjana Cvetkovic; Dusica Pavlovic
Journal:  Cell Mol Neurobiol       Date:  2013-05-16       Impact factor: 5.046

3.  Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Authors:  Wildéa Lice de Carvalho Jennings Pereira; Tamires Flauzino; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Andrea Name Colado Simão; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Neuromolecular Med       Date:  2019-08-31       Impact factor: 3.843

Review 4.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

5.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

6.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

7.  IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation.

Authors:  Rebecca A Sosa; Cathi Murphey; Rachel R Robinson; Thomas G Forsthuber
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-24       Impact factor: 11.205

8.  Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.

Authors:  Ana Paula Kallaur; Sayonara Rangel Oliveira; Andréa Name Colado Simão; Daniela Frizon Alfieri; Tamires Flauzino; Josiane Lopes; Wildea Lice de Carvalho Jennings Pereira; Caio de Meleck Proença; Sueli Donizete Borelli; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Mol Neurobiol       Date:  2016-03-29       Impact factor: 5.590

9.  Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.

Authors:  Sayonara R Oliveira; Ana Paula Kallaur; Edna M V Reiche; Damacio R Kaimen-Maciel; Carolina Panis; Marcell Alysson B Lozovoy; Helena K Morimoto; Michael Maes; Isaias Dichi; Andrea Name Colado Simão
Journal:  Mol Neurobiol       Date:  2016-03-30       Impact factor: 5.590

10.  Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.

Authors:  A P Kallaur; S R Oliveira; A N C Simão; E R D de Almeida; H K Morimoto; J Lopes; L M Pelegrino; W L C J de Pereira; Daniele Frizon Alfieri; R M Andrade; S D Borelli; M A E Watanabe; D R Kaimen-Maciel; E M V Reiche
Journal:  J Mol Neurosci       Date:  2014-04-04       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.